Published Year: 2021
Next-Generation Biomanufacturing Market - A Global Analysis: Focus on Single-Use and Digital Platfor
The global next-generation biomanufacturing market is expected to grow at a CAGR of 14.85%...
Market Research Report
A quick peek into the report
Market Overview
Market Overview - Global Viral Vector and Plasmid Manufacturing Market
The global viral vector and plasmid manufacturing market represents the market scenario of the viral vector and plasmid products and services across the world, taking into account key companies and their offerings in the market.
The advent of advanced therapies including gene therapy and cell therapy, which employ the use of vectors has created a huge buzz in the field of medicine in the past few decades. Therapies that require genetic modification, including the introduction of therapeutic DNA/gene into a patient's body or cell, demonstrated tremendous potential for the treatment of several critical diseases, including cancer, Alzheimer's disease, Parkinson's disease, and rheumatoid arthritis, among others.
A vector act as a gene delivery vehicle used for the introduction of a transgene into the targeted cell, where it can be replicated and/or expressed. The vector itself is a DNA molecule, consisting of an insert (transgene) and a larger sequence that serves as the pillar of the vector. The main role of the vector in transferring genetic information to another cell involves isolation, multiplication, or expression of the insert in the target cell.
Viral and non-viral vectors have emerged as well-organized delivery tools offering promising therapeutic approaches for previously intractable human diseases, including cancer, genetic, immunologic, neurodegenerative, ocular, as well as cardiovascular diseases, among others.
According to the market intelligence by BIS Research, global viral vector and plasmid manufacturing market was estimated at $1.16 billion in 2019 and is expected to grow at a significant double digit CAGR during the forecast period from 2020 to 2030.
|
Market Dynamics |
|||
|
Growth Drivers |
• Rising Prevalence of Cancer, Genetic Disorders, and Infectious Diseases • Rapid Uptake of Viral and Plasmid Vectors for the Development of Innovative Therapies • Increasing Number of Clinical Studies for the Development of Gene Therapy • Favorable Funding Scenario for Vector-Based Therapies |
||
|
Market Challenges |
• Unaffordable Cost of Gene Therapies • High Manufacturing Costs of Viral Vectors and Plasmids • Complications Associated with Large-Scale Production of Vectors |
||
|
Market Opportunities |
• Rising Demand for Synthetic Genes • Emergence of Next-Generation Vectors |
||
Growth Factors
- Rising prevalence of cancer, genetic disorders, and infectious diseases: Rising prevalence of cancer, genetic diseases, and infectious diseases is generating high demand for vector-based gene therapies, cell therapies, and vaccines, and therefore acting as one of the key driving factors for the growth of the global viral vector and plasmid manufacturing market. The most common types of cancers include breast cancer, lung cancer, prostate cancer, colon, and rectum cancer. Among these, lung cancer accounts for most of the cancer deaths, followed by breast cancer and colorectal cancer, according to the World Health Organization.
- Rapid uptake of viral and plasmid vectors for the development of innovative therapies: Viral and non-viral vectors are increasingly being used for the development of novel therapies. These vectors are helpful in achieving in-vivo delivery of gene to a targeted cell or tissue. Viral vectors such as adeno-associated virus, lentivirus, and retrovirus are some of the commonly used vectors utilized in several clinical and preclinical trials evaluating gene and cell therapy products as well as vaccines.
- Increasing number of clinical studies for the development of gene therapy: Currently, the global gene therapy market is witnessing an increasing number of clinical trials, offering a lucrative opportunity for the growth of viral vector and plasmid manufacturing market.
- Favorable funding scenario for vector-based therapies: Preclinical and clinical trials, analyzing the effectiveness of any therapy, require adequate funding because of the high cost involved in manufacturing and development of the new therapy. Huge availability of grants and funds for conducting research and development activities related to vector-based cell and gene therapies is actively promoting the growth of the viral vector and plasmid manufacturing market.
Report Description
|
Market Report Coverage - Global Viral Vector and Plasmid Manufacturing Market |
|||
|
Base Year |
2018 |
Market Size by 2018 |
$1,158.44 Million |
|
Forecast Period |
2020-2030 |
Value Estimation by 2030 |
$ 5,862.22 Million |
|
CAGR During Forecast Period |
16.28% |
Number of Tables |
14 |
|
Number of Pages |
275 |
Number of Figures |
157 |
|
Market Segmentation |
• Vector Type – Plasmid DNA and Viral Vector • Viral Vector Type – Adenovirus, Adeno-Associated Virus, Retrovirus, Lentivirus, Vaccinia Virus, and Other Viral Vectors • Disease Type – Cancer, Genetic Disease, Infectious Disease, Cardiovascular Disease, and Other Diseases • Application – Gene Therapy, Cell Therapy, Vaccinology, and Other Applications |
||
|
Regional Segmentation |
• North America – U.S., Canada • Europe – Germany, U.K., France, Italy, Switzerland, Belgium Spain, and Rest-of-Europe • Asia-Pacific – China, Australia, Japan, India, South Korea, Singapore, and Rest-of-Asia-Pacific • Rest-of-the-World – Latin America and Middle-East and Africa |
||
|
Key Companies Profiled |
FUJIFILM Holdings Corporation, GENERAL ELECTRIC, Lonza, Merck KGaA, MolMed S.p.A., Novasep Holding, Oxford Biomedica plc, Catalent, Inc., Thermo Fisher Scientific, Inc., GenScript, Boehringer Ingelheim, Wuxi AppTec Co., Ltd., Sartorius AG, Takara Bio Inc., and Aldevron, L.L.C. |
||
Market Segmentation
Market Outlook by Vector Type
The vector type market segment is further categorized into plasmid DNA and viral vector. Both viral vector and plasmids have gained widespread success, owing to the promising results displayed by them in preclinical and clinical studies of cell and gene therapies as well as vector-based vaccine products.
Among these two classes of vectors, viral vectors account for majority of the market share that is mainly attributable to the availability of a large variety of viral vector options in the market and the effectiveness displayed by each of them in the treatment of various diseases. The market is largely dominated by viral vectors that contributed to maximum of the total market share in 2019.
By Disease Type
The disease type segment is further categorized into cancer, genetic disease, infectious disease, cardiovascular disease, and other diseases. The global viral vector and plasmid manufacturing market, by disease, is largely dominated by the cancer segment that contributed to maximum of the total market share in 2019. The cancer segment is expected to register a double digit CAGR during the forecast period between 2020 and 2030. This is mainly attributed to the progress made in vector-based CAR-T cell therapies and increasing investments in the field of oncology for the development of advanced therapies.
However, among the different disease types, the infectious disease segment is expected to account for the highest CAGR during the forecast period between 2020 and 2030, owing to the increasing investments in the infectious disease sector, globally, for the development of advanced therapies to protect against infectious disease pandemics and outbreaks.
By Region
North America dominated the global viral vector and plasmid manufacturing market in 2019. The presence of a large number of well-equipped vector manufacturing facilities with advanced infrastructure and the strong investments in the biomanufacturing sector are significantly promoting the growth of the viral vector and plasmid manufacturing market in North America.
The North America viral vector and plasmid manufacturing is largely dominated by the U.S., owing to the rapid adoption rate of vector-based gene and cell therapy products, which has led to an increased demand for viral vectors and plasmids.
However, among all the regions, Asia-Pacific is expected to witness the highest CAGR during the forecast period between 2020 and 2030. This is mainly attributed to the strong potential of emerging nations of Asia-Pacific including Japan, India, Australia, South Korea, and Singapore, among others.
Global Viral Vector and Plasmid Manufacturing Market
Focus on Vector Type, Application, Disease, 5 Region’s Data, 15 Countries’ Data, Patent Landscape and Competitive Insights - Analysis and Forecast, 2020-2030
Similar Product
You may also like
Published Year: 2021
Global Viral and Non-Viral Vector Manufacturing Market: Focus on Vector Type, Application, Disease a
The global viral and non-viral vector manufacturing market was valued at $1.50 billion in 2020...
Published Year: 2021
Global Cell and Gene Therapy Market: Focus on Product Type, Therapeutic Class, Pipeline, Regional an
The global cell and gene therapy market was valued at $2,599.7 million in 2020, and it is...